Phase I Study of Nintedanib Incorporating Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Patients With Advanced Solid Tumors

被引：5

作者：

Lee, Chooi Peng ^{[1
,2
]}

Taylor, N. Jane ^{[3
]}

Attard, Gerhardt ^{[1
,2
]}

Pacey, Simon ^{[4
]}

Nathan, Paul D. ^{[3
]}

De Bono, Johann S. ^{[1
,2
]}

Temple, Graham ^{[5
]}

Bell, Susan ^{[5
]}

Stefanic, Martin ^{[6
]}

Stopfer, Peter ^{[6
]}

Tang, Adrian ^{[1
,2
]}

Koh, Dow-Mu ^{[1
,2
]}

Collins, David J. ^{[1
,2
,7
,8
,9
]}

d'Arcy, James ^{[1
,2
,7
,8
,9
]}

Padhani, Anwar R. ^{[3
]}

Leach, Martin D. ^{[1
,2
,7
,8
,9
]}

Judson, Ian R. ^{[1
,2
]}

Rustin, Gordon J. ^{[3
]}

机构：

[1] Royal Marsden Hosp, Sutton, Surrey, England

[2] Inst Canc Res, Sutton, Surrey, England

[3] Mt Vernon Canc Ctr, Northwood, Middx, England

[4] Univ Cambridge, Addenbrookes Hosp, Dept Oncol, Cambridge CB2 2QQ, England

[5] Boehringer Ingelheim Ltd, Bracknell, Berks, England

[6] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany

[7] Canc Res UK, Sutton, Surrey, England

[8] Royal Marsden Hosp, Canc Imaging Ctr, Engn & Phys Sci Res Council, Sutton, Surrey, England

[9] Inst Canc Res, Sutton, Surrey, England

来源：

ONCOLOGIST | 2015年 / 20卷 / 04期

关键词：

TRIPLE ANGIOKINASE INHIBITOR; RECEPTOR TYROSINE KINASES; ENDOTHELIAL GROWTH-FACTOR; CELL LUNG-CANCER; BIBF; 1120; ANGIOGENESIS INHIBITOR; CONTROLLED-TRIAL; DOUBLE-BLIND; PHARMACOKINETICS; SAFETY;

D O I：

10.1634/theoncologist.2014-0250

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background. This open-label phase I dose-escalation study investigated the safety, efficacy, pharmacokinetics (PK), and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) effects of the oral angiokinase inhibitor nintedanib in patients with advanced solid tumors. Methods. Nintedanib was administered once daily continuously, starting at 100 mg and later amended to allow evaluation of 250 mg b.i.d. The primary endpoint was maximum tolerated dose (MID). DCE-MRI studies were performed at baseline and on days 2 and 28. Results. Fifty-one patients received nintedanib 100-450 mg once daily (n = 40) or 250 mg b.i.d. (n = 11). Asymptomatic reversible liver enzyme elevations (grade 3) were dose limiting in 2 of 5 patients at 450 mg once daily. At 250 mg b.i.d., 2 of 11 patients experienced dose-limiting toxicity (grade 3 liver enzyme elevation and gastrointestinal symptoms). Common toxicities included fatigue, diarrhea, nausea, vomiting, and abdominal pain (mainly grade <= 2). Among 45 patients, 22 (49%) achieved stable disease; 7 remained on treatment for >6 months. DCE-MRI of target lesions revealed effects in some patients at 200 and >= 400 mg once daily. Conclusion. Nintedanib is well tolerated by patients with advanced solid malignancies, with MID defined as 250 mg b.i.d., and can induce changes in DCE-MRI. Disease stabilization >6 months was observed in 7 of 51 patients.

引用

页码：368 / 369

页数：2

共 21 条

[1] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[2] Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas [J].

Burris, HA ;

Hurwitz, HI ;

Dees, EC ;

Dowlati, A ;

Blackwell, KL ;

O'Neil, B ;

Marcom, PK ;

Ellis, MJ ;

Overmoyer, B ;

Jones, SF ;

Harris, JL ;

Smith, DA ;

Koch, KM ;

Stead, A ;

Mangum, S ;

Spector, NL .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5305-5313

[3] Role of anti-angiogenesis agents in treating NSCLC: Focus on bevacizumab and VEGFR tyrosine kinase inhibitors [J].

Cabebe E. ;

Wakelee H. .

Current Treatment Options in Oncology, 2007, 8 (1) :15-27

[4] Angiogenesis in cancer and other diseases [J].

Carmeliet, P ;

Jain, RK .

NATURE, 2000, 407 (6801) :249-257

[5]

du Bois A, 2013, INT J GYNECOL CANCER, V23

[6]

Hanna NH, 2013, J CLIN ONCOL, V31

[7] Pharmacokinetics and pharmacodynamics: Maximizing the clinical potential of erlotinib (Tarceva) [J].

Hidalgo, M ;

Bloedow, D .

SEMINARS IN ONCOLOGY, 2003, 30 (03) :25-33

[8] BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy [J].

Hilberg, Frank ;

Roth, Gerald J. ;

Krssak, Martin ;

Kautschitsch, Susanna ;

Sommergruber, Wolfgang ;

Tontsch-Grunt, Ulrike ;

Garin-Chesa, Pilar ;

Bader, Gerd ;

Zoephel, Andreas ;

Quant, Jens ;

Heckel, Armin ;

Rettig, Wolfgang J. .

CANCER RESEARCH, 2008, 68 (12) :4774-4782

[9] Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging [J].

Leach, M. O. ;

Morgan, B. ;

Tofts, P. S. ;

Buckley, D. L. ;

Huang, W. ;

Horsfield, M. A. ;

Chenevert, T. L. ;

Collins, D. J. ;

Jackson, A. ;

Lomas, D. ;

Whitcher, B. ;

Clarke, L. ;

Plummer, R. ;

Judson, I. ;

Jones, R. ;

Alonzi, R. ;

Brunner, T. ;

Koh, D. M. ;

Murphy, P. ;

Waterton, J. C. ;

Parker, G. ;

Graves, M. J. ;

Scheenen, T. W. J. ;

Redpath, T. W. ;

Orton, M. ;

Karczmar, G. ;

Huisman, H. ;

Barentsz, J. ;

Padhani, A. .

EUROPEAN RADIOLOGY, 2012, 22 (07) :1451-1464

[10] The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations [J].

Leach, MO ;

Brindle, KM ;

Evelhoch, JL ;

Griffiths, JR ;

Horsman, MR ;

Jackson, A ;

Jayson, GC ;

Judson, IR ;

Knopp, MV ;

Maxwell, RJ ;

McIntyre, D ;

Padhani, AR ;

Price, P ;

Rathbone, R ;

Rustin, GJ ;

Tofts, PS ;

Tozer, GM ;

Vennart, W ;

Waterton, JC ;

Williams, SR ;

Workmanw, P .

BRITISH JOURNAL OF CANCER, 2005, 92 (09) :1599-1610

← 1 2 3 →